Figures & data
Figure 1. Mechanisms of action of belantamab mafodotin. The interaction between the drug and BCMA promotes the activation of caspase-3 dependent apoptosis after the intracellular release of MMAF. The afucosylation of the antibody permits the linkage with the Fc-bearing NK cells, inducing antibody-dependent cellular cytotoxicity (ADCC). Another mechanism of cell death is mediated by macrophages via antibody-dependent cellular phagocytosis (ADCP) following the release of antigens by apoptotic MM cells.
![Figure 1. Mechanisms of action of belantamab mafodotin. The interaction between the drug and BCMA promotes the activation of caspase-3 dependent apoptosis after the intracellular release of MMAF. The afucosylation of the antibody permits the linkage with the Fc-bearing NK cells, inducing antibody-dependent cellular cytotoxicity (ADCC). Another mechanism of cell death is mediated by macrophages via antibody-dependent cellular phagocytosis (ADCP) following the release of antigens by apoptotic MM cells.](/cms/asset/5eb5758a-7a69-466a-8db6-610aee46d60a/iebt_a_2218543_f0001_oc.jpg)
Table 1. Selected clinical trials of belantamab mafodotin regimens.